Table 2. Pharmacological evaluation analogues 1e and 6j-u, tested at 10 μM against an ACh-mediated concentration-response curve.

Compound #	R1	Δbaselinea	ΔpEC50	ΔEmaxb
1e		103.2 ± 2.85	1.48 ± 0.20	44.7 ± 2.74
6j		32.1 ± 2.52*	1.15 ± 0.10	21.8 ± 2.97*
6k		51.4 ± 9.53*	0.76 ± 0.26*	128.8 ± 9.68
6l		8.48 ± 4.01*	1.27 ± 0.15	5.60 ± 4.45*
6m		88.1 ± 4.09	1.31 ± 0.17	80.6 ± 4.78*
6n		51.7 ± 4.21*	1.35 ± 0.17	53.5 ± 5.54
6o		33.2 ± 4.25*	0.25 ± 0.11*	97.7 ± 4.47*
6p		78.2 ± 5.58*	1.99 ± 0.19	61.3 ± 3.81
6q		77.3 ± 3.17*	1.33 ± 0.13	65.6 ± 3.48*
6r		52.2 ± 5.62*	1.63 ± 0.17	57.7 ± 4.85
6s		89.7 ± 6.11	2.57 ± 0.25*	73.3 ± 7.00*
6t		83.3 ± 4.16*	2.11 ± 0.18*	50.5 ± 3.60
6u		18.6 ± 3.70*	1.24 ± 0.11	39.0 ± 3.53

Data represent the mean ± SEM of 4 independent experiments performed in duplicate. Only the change in pEC₅₀, baseline and E_max for the 10 μM concentrations of PAMs are reported, with the full ACh concentration-response curves in the presence of 1 μM and 10 μM PAMs shown in Supp. Fig. 3. Data were analysed by one-way ANOVA and compared to the control PAM, 1e, with a post-hoc Dunnett test

where *p < 0.05 was considered to be significantly different.

^aΔbaseline is expressed as a percentage of the maximum ACh response in the absence of PAM.

^bΔE_max is expressed as a percentage of the maximum ACh response in the absence of PAM.